|
|
Article: Study Shows GlaxoSmithKline's Requip(R) (ropinirole HCl) Tablets Effectively Treats Symptoms of Primary Restless Legs Syndrome and Improves Sleep and Quality of Life in Patients.
- Article from:
- PR Newswire
- Article date:
- December 15, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Study results published today in the journal Movement Disorders show that Requip(R)(ropinirole HCl) Tablets effectively treats the symptoms of primary Restless Legs Syndrome (RLS) as assessed by improvements in symptoms, over 12 weeks. Improvements were seen as early as one week. The study of 267 patients, one of the largest placebo-controlled trials of a treatment for RLS conducted to-date, also showed significant improvements in sleep and quality of life in RLS patients taking Requip versus placebo. Requip is under review by the U.S. Food and Drug Administration (FDA) for the treatment of the signs and symptoms of primary RLS. There is no FDA-approved treatment for RLS ...